Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
EPO doping drug can reduce cerebral malaria related deaths

EPO doping drug can reduce cerebral malaria related deaths

Prism Pharmaceuticals to be acquired by Baxter

Prism Pharmaceuticals to be acquired by Baxter

bluebird bio announces receipt of additional $30 million in financing

bluebird bio announces receipt of additional $30 million in financing

Rituxan receives FDA approval for treating two rare diseases

Rituxan receives FDA approval for treating two rare diseases

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Positive interim anemia response data from YM's CYT387 Phase I/II trial in myelofibrosis

Positive interim anemia response data from YM's CYT387 Phase I/II trial in myelofibrosis

FDA approval of Pipeline Embolization Device offers better options for treatment of large/giant aneurysms

FDA approval of Pipeline Embolization Device offers better options for treatment of large/giant aneurysms

Novocure receives FDA approval for NovoTTF-100A System to treat GBM

Novocure receives FDA approval for NovoTTF-100A System to treat GBM

Plasma biomarkers can predict risk of metastasis in patients with melanoma

Plasma biomarkers can predict risk of metastasis in patients with melanoma

Experts to discuss latest findings in IBD research at Rome meeting

Experts to discuss latest findings in IBD research at Rome meeting

Hunters' lead ammunition finds way into scavenger birds leading to blindness, seizures and death

Hunters' lead ammunition finds way into scavenger birds leading to blindness, seizures and death

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

Alnylam defends against Tekmira complaint, files answer and counterclaim

Alnylam defends against Tekmira complaint, files answer and counterclaim

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.